奇孔尼亚病毒样颗粒疫苗对安全性和耐受性结果的影响:随机临床试验
Grace L Chen1, Emily E Coates1, Sarah H Plummer1
1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
JAMA
|April 15, 2020
概括
一种基孔尼亚病毒样粒子 (VLP) 疫苗在流行地区的成年人中显示出安全性和耐受性. 需要进行进一步的第三期试验,以确认其对蚊子传播疾病的临床疗效.
科学领域:
- 病毒学
- 免疫学
- 疫苗学
背景情况:
- chikungunya病毒 (CHIKV) 是蚊子传播的广泛存在的阿尔法病毒.
- 目前,没有获得许可的疫苗或治疗方法可以治疗CHIKV感染.
研究的目的:
- 评估试验中的CHIKV病毒样颗粒 (VLP) 疫苗的安全性和耐受性.
- 在特有群体中评估CHIKV VLP疫苗的免疫性.
主要方法:
- 这是一项随机,安慰剂控制,双盲的2期临床试验,涉及CHIKV流行地区的400名健康成年人.
- 参与者接受了两次肌肉内注射CHIKVVLP疫苗 (20微克) 或安慰剂,隔28天.
- 在72周内评估了安全性,耐受性和免疫反应 (中和试验).
主要成果:
- CHIKV VLP疫苗的耐受性很好,与研究药物无关的严重不良事件在两组之间没有显著差异.
- 可能与疫苗相关的轻度至中度不良反应是暂时的,并没有发生后果.
- 与安慰剂相比,接种疫苗导致中和抗体几何平均标位 (GMT) 显著增加,免疫反应持续长达72周.
结论:
- 在居住在CHIKV流行地区的健康成年人中,CHIKV VLP疫苗具有良好的安全性和耐受性.
- 疫苗会产生强大而持久的中和抗体反应.
- 需要进行第三期试验,以评估CHIKV VLP疫苗的临床疗效.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
1.1K
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
9.1K
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
91
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
91
Bioavailability Study Design: Single Versus Multiple Dose Studies
137
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
137
Bioequivalence studies: Biowaivers
149
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
149
